Cullinan Therapeutics (CGEM) CEO awarded 828,000 stock options grant

Rhea-AI Filing Summary

Cullinan Therapeutics reported that President and CEO Nadim Ahmed was granted a stock option covering 828,000 shares of common stock. The option was awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.

According to the disclosure, the shares underlying the option vest over four years, with one forty-eighth of the option shares vesting in equal monthly installments until the fourth anniversary of the grant date. After this grant, the CEO held options covering 828,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider AHMED NADIM

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	828,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 828,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AHMED NADIM

(Last) (First) (Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.44	02/18/2026		A		828,000		(1)	02/18/2036	Common Stock	828,000	$0	828,000	D

Explanation of Responses:

1. The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cullinan Therapeutics (CGEM) disclose for Nadim Ahmed?

Cullinan Therapeutics disclosed that President and CEO Nadim Ahmed received a grant of stock options for 828,000 shares. These options were awarded as a compensatory grant rather than an open-market purchase, and are reported as a derivative security on a Form 4 filing.

How many Cullinan Therapeutics (CGEM) shares are covered by the new CEO option grant?

The new option grant to the Cullinan Therapeutics CEO covers 828,000 shares of common stock. This entire amount is reported as held following the transaction, indicating it is a single, newly awarded equity incentive grant under the company’s compensation arrangements.

What is the exercise price of Nadim Ahmed’s Cullinan Therapeutics stock options?

The exercise price of Nadim Ahmed’s Cullinan Therapeutics stock options is disclosed as $0.00 per share. This zero exercise price emphasizes that the grant functions as equity-based compensation rather than a purchase requiring cash payment upon exercise.

How do the Cullinan Therapeutics CEO’s 828,000 options vest over time?

The 828,000 options granted to the Cullinan Therapeutics CEO vest over four years. One forty-eighth of the total grant vests in equal monthly installments until the fourth anniversary of the grant date, creating a long-term, time-based vesting schedule.

Is the Cullinan Therapeutics CEO’s Form 4 transaction a stock purchase or an award?

The Cullinan Therapeutics CEO’s Form 4 transaction is described as a grant or award acquisition, not an open-market stock purchase. It reports a compensatory stock option covering 828,000 shares at a $0.00 exercise price, classified as a derivative security.

What type of security was reported in Cullinan Therapeutics (CGEM) CEO’s Form 4?

The Form 4 reports a derivative security described as a “Stock Option (Right to Buy).” This option gives the Cullinan Therapeutics CEO the right to acquire up to 828,000 common shares, subject to the four-year monthly vesting conditions detailed in the filing footnote.